Key result
Radical surgery, chemotherapy, and radiotherapy achieve 1-year survival in a rare AV fistula angiosarcoma.
Why the study?
Angiosarcoma occurring at an arteriovenous fistula site is exceptionally rare and prone to misdiagnosis.
Case Report (n=1)
Angiosarcoma can rarely develop at arteriovenous fistula sites in renal transplant recipients, requiring high clinical suspicion for early diagnosis and treatment.
May support multimodal therapy for rare AVF angiosarcoma in transplant recipients; leaves open optimal regimens and generalizability.
Angiosarcoma is a rare and aggressive malignant tumor arising from vascular or lymphatic endothelial cells. Angiosarcoma at an arteriovenous fistula site is exceptionally rare. We report a case of a 37-year-old male renal transplant recipient who developed a high-grade epithelioid angiosarcoma at the site of an arteriovenous fistula six years post-transplant. The lesion presented as a bleeding, enlarging mass and was initially misdiagnosed, delaying definitive treatment. A biopsy confirmed the diagnosis, and the patient underwent radical surgery, chemotherapy, and radiotherapy. This case highlights the need for heightened clinical suspicion, particularly in patients with arteriovenous fistula-related complications, as early diagnosis and treatment are crucial for this rare but aggressive malignancy.
No takes yet. Share an insight, caveat, or question.
Aoun et al. (2024) conducted a case report in Angiosarcoma at an arteriovenous fistula site (n=1). Shoulder disarticulation, chemotherapy, and radiotherapy was evaluated on Patient survival and disease progression. A 37-year-old male renal transplant recipient with a rare high-grade epithelioid angiosarcoma at an arteriovenous fistula site was successfully treated with radical surgery, chemotherapy, and radiotherapy, remaining alive at one year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: